MMJ BioPharma Cultivation To Produce Quality Cannabis, Meeting DEA's Definition Of Chemical Reproducibility

MMJ BioPharma Cultivation, a company, received its DEA schedule 1 Analytical Lab Registration, which allows for the international importation of for and development.

In addition, MMJ BioPharma has been awarded FDA “Orphan Designation” for its clinical trial in Huntington’s Disease. The company also has an investigational new drug (IND) application filed with the FDA to begin clinical trials in Multiple Sclerosis. Meanwhile, MMJ is awaiting the DEA to issue its bulk manufacturing registration.

“MMJ has filed suit against the DEA for dragging their feet on the matter of not issuing the registration in a timely manner. Currently, MMJ BioPharma is nearing completion of its state-of-the-art, marijuana center of excellence,” stated the firm in a press release on Tuesday.

"As MMJ International Holdings continues to advance to its clinical trials, these DEA delays are unprecedented," stated Elio Mariani, Ph.D., CEO of MMJ. "The statutory mandate of the DEA is security …

Full story available on Benzinga.com

More MMJ BioPharma Cultivation To Produce Quality Cannabis, Meeting DEA's Definition Of Chemical Reproducibility